Antiangiogenic approaches for the treatment of advanced synovial sarcomas

Current Opinion in Oncology

Volumn 24, Issue 4, 2012, Pages 425-430

  Do, Khanh ^a   Doroshow, James H ^a,b   Kummar, Shivaani ^a,b  

^a Center for Cancer Research   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

anti vascular endothelial growth factor therapy; hepatocyte growth factor receptor; synovial sarcoma

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BRIVANIB; CEDIRANIB; CISPLATIN; DOXORUBICIN; FIBROBLAST GROWTH FACTOR; IFOSFAMIDE; MITOMYCIN; PAZOPANIB; SORAFENIB; SUNITINIB; THALIDOMIDE; TIVANTINIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE COURSE; DRUG MEGADOSE; FOLLOW UP; HUMAN; META ANALYSIS (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYNOVIAL SARCOMA; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; SARCOMA, SYNOVIAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84862140598     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328354c141     Document Type: Review

References (36)

1. Lee W, Han K, Harris CP, et al. Use of FISH to detect chromosomal translocations and deletions. Analysis of chromosome rearrangement in synovial sarcoma cells from paraffin-embedded specimens. Am J Pathol 1993; 143:15-19. (Pubitemid 24058156)
2. Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 2004; 101:627-634. (Pubitemid 38970615)
3. Skubitz KM, D'Adamo DR. Sarcoma. Mayo Clin Proc 2007; 82:1209-1432.
4. Trassard M, Le Doussal V, Hacene K, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol 2001; 19:525-534. (Pubitemid 32112867)
5. Lewis JJ, Antonescu CR, Leung DH, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 2000; 18:2087-2094. (Pubitemid 30324362)
6. Spurrell EL, Fisher C, Thomas JM, et al. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol 2005; 16:437-444. (Pubitemid 40458321)
7. Sarcoma Meta-analysis Collaboration (SMAC). Adjuvant chemotherapy for localized resectable soft tissue sarcoma in adults. Cochrane Database Syst Rev 2000; 4:1-6.
8. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11:1269-1275. (Pubitemid 23199129)
9. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 1994; 73:2506-2511. (Pubitemid 24155525)
10. Olsson A-K, Dimberg A, Kreuger J, et al. VEGF receptor signaling: in control of vascular function. Nature Rev 2006; 7:359-371.
11. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676. (Pubitemid 36749215)
12. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998; 95:548-553. (Pubitemid 28083780)
13. Hicklin DJ, Ellis JM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-1027. (Pubitemid 46202320)
14. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298-307.
15. Yoon SS, Segal NH, Park P, et al. Angiogenic profiling of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Res 2006; 135:282-290. (Pubitemid 44414877)
16. Rini BI, Garcia JA, Cooney MM, et al. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 2009; 15:6277-6283.
17. Yi-Shin Kuo D, Timmins P, Blank SV, et al. Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium. Gynecol Oncol 2006; 100:160-165. (Pubitemid 41815067)
18. D'Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft tissue sarcomas. J Clin Oncol 2005; 23:7135-7142.
19. George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009; 27:3154-3160.
20. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27:3133-3140.
21. Fox E, Aplenc R, Bagatell R, et al. A phase I trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 2010; 28:5174-5181.
22. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organization for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27:3126-3132.
23. Schwartz GK, Maki RG, Ratain MJ, et al. Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial. J Clin Oncol 2011; 29 (suppl): abstr 10000.
24. Oda Y, Sakamoto A, Saito T, et al. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-met correlates with poor prognosis in synovial sarcoma. Hum Path 2000; 31:185-192. (Pubitemid 30090647)
25. Sierra JR, Tsao MS. c-Met as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 2011; 3:S21-35.
26. Bussolino F, Di RenzoMF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992; 119:629-641.
27. Xin X, Yang S, Ingle G, et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 2001; 158:1111-1120. (Pubitemid 32221803)
28. Gerritsen ME, Tomlinson JE, Zlot C, et al. Using gene expression profiling to identify the molecular basis of the synergistic action of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol 2003; 140:595-610. (Pubitemid 37386423)
29. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3:347-361. (Pubitemid 38340304)
30. Wen PY. American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section. Expert Rev Anticancer Ther 2010; 10:1367-1369.
31. Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. J Clin Oncol 2011; 29 (suppl): abstr 4516.
32. Gordon MS, Vogelzang NJ, Schoffski P, et al. Activity of cabozantinib (XL184) in soft tissue and bone: Results from a phase II randomized discontinuation trial (RDT) in patients with advanced solid tumors. J Clin Oncol 2011; 29 (suppl): abstr 3010.
33. Eder JP, Shapiro GI, Appleman LJ, et al. A phase I study of foretinib, a multitargeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010; 16:3507-3516.
34. Francis P, Namlos HM, Muller C, et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 2007; 8:73.
35. Friedrichs N, Trautmann M, Endl E, et al. Phosphatidylinositol-3'-kinase/ AKT signaling is essential in synovial sarcoma. Int J Cancer 2011; 129:1564-1575.
36. Neghandhi AM, Milhem MM. A combination of sorafenib, nelfinavir, and sirolimus in a patient with progressive metastatic synovial sarcoma after chemotherapy. J Clin Oncol 2011; 29 (suppl): abstr e20531.